Halozyme Therapeutics P/E Ratio

Halozyme Therapeutics (HALO) currently reports a P/E ratio of 30.45. That is above the Healthcare sector average of 24.78. Use the charts on this page to explore Halozyme Therapeutics's P/E ratio history and peer comparisons.

Halozyme Therapeutics's P/E ratio of 30.45 is higher than the Healthcare sector average of 24.78. That is roughly 22.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Halozyme Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At 30.45, HALO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 30.45, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 24.78. From there, open related valuation or income-statement pages for Halozyme Therapeutics, and consider following HALO for alerts when major investors trade the stock.

Halozyme Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows 30.45 versus a sector average near 24.78. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HALO with unrelated industries.